Clinical Trial Update: Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing standard chemotherapy vs immunotherapy as second-line treatment for MSI-high metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Immunotherapy (PD-1 inhibitor)
• Standard chemotherapy regimen

Snippet

Sponsor: Federation Francophone de Cancerologie Digestive | Conditions: Metastatic Colorectal Cancer, MSI | Phase 2 | Status: COMPLETED